Roche Poised For Growth Amid Obesity-Drug Ambitions -- Market Talk

Dow Jones

Mar 26, 2025

0849 GMT - Roche is well positioned for growth in the medium-term on expedited obesity-drug ambitions, Baader Helvea analyst Abhishek Raval says in a note. The Swiss pharmaceutical company recently acquired a mid-stage weight-loss drug candidate from Danish biotech Zealand Pharma. The company also has a diversified portfolio of disease areas, Raval notes. "With significant manufacturing and commercial might...the Swiss giant could become a serious contender in the obesity market," he says. Historically, Roche has usually been the market-leader in many of the disease areas it targets, the analyst says. Any progress in Roche's obesity pipeline could fuel the already solid share-price performance in recent months, he adds. Shares fall 0.9% to 302.90 Swiss francs. (helena.smolak@wsj.com)

(END) Dow Jones Newswires

March 26, 2025 04:49 ET (08:49 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2522984516"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2522984516\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2522984516?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-26 16:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2522984516","market":"sh","top_or_hot":-1,"title":"Roche Poised For Growth Amid Obesity-Drug Ambitions -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0849 GMT - Roche is well positioned for growth in the medium-term on expedited obesity-drug ambitions, Baader Helvea analyst Abhishek Raval says in a note. The Swiss pharmaceutical company recently acquired a mid-stage weight-loss drug candidate from Danish biotech Zealand Pharma. The company also has a diversified portfolio of disease areas, Raval notes. \"With significant manufacturing and commercial might...the Swiss giant could become a serious contender in the obesity market,\" he says. Historically, Roche has usually been the market-leader in many of the disease areas it targets, the analyst says. Any progress in Roche's obesity pipeline could fuel the already solid share-price performance in recent months, he adds. Shares fall 0.9% to 302.90 Swiss francs. (helena.smolak@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 26, 2025 04:49 ET (08:49 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roche Poised For Growth Amid Obesity-Drug Ambitions -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoche Poised For Growth Amid Obesity-Drug Ambitions -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-03-26 16:49</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0849 GMT - Roche is well positioned for growth in the medium-term on expedited obesity-drug ambitions, Baader Helvea analyst Abhishek Raval says in a note. The Swiss pharmaceutical company recently acquired a mid-stage weight-loss drug candidate from Danish biotech Zealand Pharma. The company also has a diversified portfolio of disease areas, Raval notes. \"With significant manufacturing and commercial might...the Swiss giant could become a serious contender in the obesity market,\" he says. Historically, Roche has usually been the market-leader in many of the disease areas it targets, the analyst says. Any progress in Roche's obesity pipeline could fuel the already solid share-price performance in recent months, he adds. Shares fall 0.9% to 302.90 Swiss francs. (helena.smolak@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 26, 2025 04:49 ET (08:49 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2522984516","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2522984516","pubTimestamp":1742978940,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0849 GMT - Roche is well positioned for growth in the medium-term on expedited obesity-drug ambitions, Baader Helvea analyst Abhishek Raval says in a note. The Swiss pharmaceutical company recently acquired a mid-stage weight-loss drug candidate from Danish biotech Zealand Pharma. The company also has a diversified portfolio of disease areas, Raval notes. \"With significant manufacturing and commercial might...the Swiss giant could become a serious contender in the obesity market,\" he says. Historically, Roche has usually been the market-leader in many of the disease areas it targets, the analyst says. Any progress in Roche's obesity pipeline could fuel the already solid share-price performance in recent months, he adds. Shares fall 0.9% to 302.90 Swiss francs. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","RHHBY":"罗氏控股","03165":"华夏欧优股对冲"},"translate_title":"罗氏有望在肥胖药物雄心中实现增长——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03165":0.6,"RHHBY":0.9},"content_text":"0849 GMT - Roche is well positioned for growth in the medium-term on expedited obesity-drug ambitions, Baader Helvea analyst Abhishek Raval says in a note. The Swiss pharmaceutical company recently acquired a mid-stage weight-loss drug candidate from Danish biotech Zealand Pharma. The company also has a diversified portfolio of disease areas, Raval notes. \"With significant manufacturing and commercial might...the Swiss giant could become a serious contender in the obesity market,\" he says. Historically, Roche has usually been the market-leader in many of the disease areas it targets, the analyst says. Any progress in Roche's obesity pipeline could fuel the already solid share-price performance in recent months, he adds. Shares fall 0.9% to 302.90 Swiss francs. (helena.smolak@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 26, 2025 04:49 ET (08:49 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}